Physician profile
Michael Timothy Gette
NPI 1083617955
$2,026.00
in general payments reported to CMS, 2019-2025
15 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $310 · 2022: $367 · 2023: $202 · 2024: $402 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.56 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $404.27 | 2019-2025 | |
| Janssen Biotech, INC. | $387.57 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $149.53 | 2020-2023 | Ilumya |
| Leo Pharma INC. | $105.36 | 2020-2024 | Adbry |
| Prugen, INC. Pharmaceuticals | $84.82 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $57.24 | 2019-2022 | |
| Genentech USA, INC. | $46.78 | 2022 | |
| Ucb, INC. | $46.66 | 2022 | |
| Janssen Scientific Affairs, LLC | $37.99 | 2022 | |
| Pfizer INC. | $35.73 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.06 | 2022 | |
| Incyte Corporation | $16.93 | 2023 | Opzelura |
| Genzyme Corporation | $14.84 | 2024 | |
| Dermavant Sciences, INC. | $13.28 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.